BRPI0813789A2 - Potenciação de quimioterapia contra câncer - Google Patents

Potenciação de quimioterapia contra câncer

Info

Publication number
BRPI0813789A2
BRPI0813789A2 BRPI0813789-7A2A BRPI0813789A BRPI0813789A2 BR PI0813789 A2 BRPI0813789 A2 BR PI0813789A2 BR PI0813789 A BRPI0813789 A BR PI0813789A BR PI0813789 A2 BRPI0813789 A2 BR PI0813789A2
Authority
BR
Brazil
Prior art keywords
against cancer
therapy against
chemotherapy therapy
chemotherapy
cancer
Prior art date
Application number
BRPI0813789-7A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Aktham Aburub
Marcio Chedid
Thomas Albert Engler
Venkatraghavan Vasudevan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39737054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0813789(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0813789A2 publication Critical patent/BRPI0813789A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0813789-7A2A 2007-07-02 2008-06-20 Potenciação de quimioterapia contra câncer BRPI0813789A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94751207P 2007-07-02 2007-07-02
PCT/US2008/067614 WO2009006043A2 (en) 2007-07-02 2008-06-20 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Publications (1)

Publication Number Publication Date
BRPI0813789A2 true BRPI0813789A2 (pt) 2014-12-30

Family

ID=39737054

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813789-7A2A BRPI0813789A2 (pt) 2007-07-02 2008-06-20 Potenciação de quimioterapia contra câncer

Country Status (22)

Country Link
US (2) US8318713B2 (cg-RX-API-DMAC7.html)
EP (1) EP2173348B1 (cg-RX-API-DMAC7.html)
JP (2) JP5551589B2 (cg-RX-API-DMAC7.html)
KR (1) KR101230085B1 (cg-RX-API-DMAC7.html)
CN (2) CN101743005B (cg-RX-API-DMAC7.html)
AR (1) AR067112A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008270732B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813789A2 (cg-RX-API-DMAC7.html)
CA (1) CA2691587C (cg-RX-API-DMAC7.html)
CL (2) CL2008001848A1 (cg-RX-API-DMAC7.html)
EA (2) EA023697B1 (cg-RX-API-DMAC7.html)
ES (1) ES2561202T3 (cg-RX-API-DMAC7.html)
IL (2) IL202237A (cg-RX-API-DMAC7.html)
MA (1) MA31677B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009013449A (cg-RX-API-DMAC7.html)
MY (1) MY154472A (cg-RX-API-DMAC7.html)
NZ (1) NZ581355A (cg-RX-API-DMAC7.html)
PE (1) PE20090838A1 (cg-RX-API-DMAC7.html)
TW (1) TWI428132B (cg-RX-API-DMAC7.html)
UA (1) UA97400C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009006043A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908725B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
EP2419106A1 (en) * 2009-04-14 2012-02-22 Eli Lilly and Company Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
EP2747761A1 (en) * 2011-09-22 2014-07-02 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
US20180110780A1 (en) * 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10016507B2 (en) * 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
AU2017386417B2 (en) * 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2022256656A1 (en) * 2021-06-03 2022-12-08 University Of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1483265B1 (en) 2002-03-05 2006-11-22 Eli Lilly And Company Purine derivatives as kinase inhibitors
ATE378336T1 (de) 2002-09-19 2007-11-15 Schering Corp Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
US20110293746A1 (en) * 2004-07-09 2011-12-01 Agency For Science, Technology And Research Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
US20060252082A1 (en) * 2005-05-04 2006-11-09 University Of South Florida Predicting treatment response in cancer subjects
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化

Also Published As

Publication number Publication date
CN101743005B (zh) 2013-06-12
MA31677B1 (fr) 2010-09-01
HK1141236A1 (zh) 2010-11-05
WO2009006043A2 (en) 2009-01-08
PE20090838A1 (es) 2009-07-02
CN101743005A (zh) 2010-06-16
CN102772416A (zh) 2012-11-14
EP2173348B1 (en) 2015-12-09
IL218443A0 (en) 2012-04-30
IL202237A (en) 2014-05-28
US8318713B2 (en) 2012-11-27
CL2011003046A1 (es) 2012-08-24
JP2014114297A (ja) 2014-06-26
JP5551589B2 (ja) 2014-07-16
AR067112A1 (es) 2009-09-30
MY154472A (en) 2015-06-30
AU2008270732B2 (en) 2013-01-31
EA018447B1 (ru) 2013-08-30
EA201070085A1 (ru) 2010-04-30
US20100166884A1 (en) 2010-07-01
CL2008001848A1 (es) 2009-05-29
US8648063B2 (en) 2014-02-11
AU2008270732A1 (en) 2009-01-08
KR20100017984A (ko) 2010-02-16
MX2009013449A (es) 2010-01-15
IL202237A0 (en) 2010-06-16
UA97400C2 (uk) 2012-02-10
TWI428132B (zh) 2014-03-01
JP2010532364A (ja) 2010-10-07
EA023697B1 (ru) 2016-07-29
WO2009006043A3 (en) 2009-04-16
TW200911272A (en) 2009-03-16
US20130039996A1 (en) 2013-02-14
EA201201155A1 (ru) 2014-11-28
ZA200908725B (en) 2011-02-23
NZ581355A (en) 2012-04-27
EP2173348A2 (en) 2010-04-14
CA2691587A1 (en) 2009-01-08
CA2691587C (en) 2013-09-24
KR101230085B1 (ko) 2013-02-05
ES2561202T3 (es) 2016-02-25

Similar Documents

Publication Publication Date Title
BRPI0813789A2 (pt) Potenciação de quimioterapia contra câncer
EP2127671A4 (en) THERAPEUTIC CANCER
BRPI0911147A2 (pt) fármaco contra câncer de fígado
ZA201004403B (en) Therapeutic cancer treatments
BRPI1006438A2 (pt) terapia adjuvante de cancer
BR112012005594A2 (pt) tratamento de câncer
ZA200807934B (en) Cancer treatments
BRPI0810206A2 (pt) Método de tratar câncer
DK2121139T3 (da) Formulations for cancer treatment
BR112012002797A2 (pt) tratamento de câncer de próstata
DK2219683T3 (da) Målrettet radioterapi
DK2147122T3 (da) Enzymatisk kræftbehandling
EP2283862A4 (en) ANTITUMOR AGENT
BRPI0922884A2 (pt) compostos para tratamento de câncer
HUE038563T2 (hu) Rák kezelési eljárás
GB0707556D0 (en) Treatment for cancer
AP2012006202A0 (en) Cancer starvation therapy.
BRPI0815772A2 (pt) Tratamento de câncer de pulmão
GB0809046D0 (en) Cancer treatment
GB0710871D0 (en) Cancer treatment
GB0706538D0 (en) Cancer therapeutic
AU2008902090A0 (en) Cancer Therapy
GB0723503D0 (en) Cancer treatment
GB0700493D0 (en) Cancer treatment
GB0706537D0 (en) Transcutaneous cancer therapeutic

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]